Background. Cardiovascular autonomic dysfunction is an early marker for cardiovascular disease. Anthracycline chemotherapy and left-sided radiation for breast cancer are associated with negative autonomic function changes. This study's objectives were to characterize changes in, and the association of exercise training with, clinical indices of cardiovascular autonomic function across the trajectory of breast cancer therapy. Subjects, Materials, and Methods. Seventy-three patients receiving adjuvant chemotherapy participated to varying degrees in supervised aerobic and resistance exercise during chemotherapy AE radiation and for 20 weeks after. Resting heart rate (HR rest ) and blood pressure were measured weekly during chemotherapy. HR rest , exercise heart rate recovery (HR recovery ), and aerobic fitness were measured at enrollment, end of chemotherapy AE radiation, and 10 and 20 weeks after treatment. Results. During chemotherapy, HR rest increased in a parabolic manner within a single treatment and with increasing treatment dose, whereas systolic and diastolic blood pressure decreased linearly across treatments. Tachycardia and hypotension were present in 32%-51% of participants. Factors associated with weekly changes during chemotherapy included receiving anthracyclines or trastuzumab, days since last treatment, hematocrit, and exercise attendance. Receipt of anthracyclines, trastuzumab, and left-sided radiation individually predicted impairments of HR rest and HR recovery during chemotherapy AE radiation; however, aerobic fitness change and at least twice-weekly exercise attendance predicted improvement. By 10 weeks after treatment, HR rest and blood pressure were not different from prechemotherapy. Conclusion. In this study, chemotherapy resulted in increased HR rest and tachycardia, as well as decreased blood pressure and hypotension. Anthracyclines, trastuzumab, and left-sided radiation were associated with HR rest elevations and impairments of HR recovery , but exercise training at least twice a week appeared to mitigate these changes. The Oncologist 2019;24:273-284
INTRODUCTION
Breast cancer survivors are at an elevated risk of cardiovascular disease [1] and are more likely to die of cardiovascular disease than women who have not had breast cancer [2] .
Proposed contributing factors to this risk include presence of comorbid conditions at diagnosis, reduced physical activity and aerobic fitness during and after treatment, early menopause induced by chemotherapy, and direct cardiovascular effects from chemotherapy, mediastinal radiotherapy, and targeted therapy [3, 4] . Cardiovascular autonomic dysfunction, impairments in the normal regulation of sympathetic and parasympathetic nervous influences on the heart and vasculature, is an early marker for cardiovascular disease-related morbidity and mortality [5] . Anthracycline chemotherapeutic agents and radiotherapy have been linked to negative autonomic changes [6] . The weight gain and reduced fitness common with breast cancer have also been associated with autonomic dysfunction in noncancer populations [6] . Aerobic and resistance exercise training have been suggested as potential therapies for prevention and treatment of autonomic impairment in breast cancer survivors [6] .
Several simple, clinically accessible measures reflect cardiovascular autonomic function and have wellestablished prognostic value for cardiovascular disease, including resting heart rate (HR rest ), resting blood pressure, and heart rate recovery following exercise (HR recovery ) [7, 8] . The latter is a simple measure that could be acquired from a clinical stress test performed in conjunction with a cardio-oncology clinic or by patient self-monitoring using a physical activity device with telemetry (e.g., Fitbit). The study team has commonly observed large fluctuations in HR rest and blood pressure during chemotherapy among women with breast cancer in both clinical care and research settings. To our knowledge, these fluctuations have not previously been reported in the literature. These chemotherapy-related changes in vital signs could have a number of implications for the clinical care of individuals receiving chemotherapy, including for clinical monitoring of patient response to treatment, interpreting patient-reported symptoms (e.g., high heart rate or dizziness), and requirement for dose adjustments of prescribed exercise or medication (e.g., for hypertension). This study is an ancillary study of these clinically accessible measures reflecting cardiovascular autonomic function measured throughout the Nutrition and Exercise during adjuvant Treatment (NExT) trial [9] . NExT exercise programming was delivered in a realworld setting, resulting in a wide range of adherence, and therefore a range of exercise volume received among participants, which enables dose-response analysis. The primary objective of this ancillary study was to characterize and explain the changes in HR rest and resting blood pressure across the trajectory of adjuvant therapy in women with breast cancer participating in an exercise program. The secondary purpose was to assess whether receipt of cardiotoxic treatments and the extent of exercise performed are associated with changes in HR rest and HR recovery during or after treatment.
PATIENTS, MATERIALS, AND METHODS

Study Design and Patients
Patients included women with stage I-IIIA breast cancer who were scheduled to receive adjuvant chemotherapy (NCT01806181). Patients were eligible to enroll up to 2 weeks before chemotherapy ("prechemotherapy") to within completion of half of planned chemotherapy treatments. Exclusion criteria included uncontrolled or unstable cardiovascular disease or diabetes, body mass index (BMI) >40 kg/m 2 , use of mobility aids, and stage IV/metastatic disease. Women with stage IV disease were excluded from the main trial because of the potential need for a different format of exercise programming (e.g., one-on-one training for increased supervision and more exercise prescription modification). The British Columbia Cancer Agency Research Ethics Board approved this study (#H12-02504). Participants provided written informed consent.
All participants were invited to attend supervised sessions consisting of 20-30 minutes each of moderate-tovigorous-intensity (50%-75% of heart rate [HR] reserve/ one-repetition maximum) aerobic and whole-body resistance exercise up to three times per week and were encouraged to perform 1-2 home-based aerobic sessions throughout chemotherapy, and radiation if received (CT AE RT). Following CT AE RT completion, two supervised and three home-based sessions per week were encouraged for 10 weeks, and then one supervised and four home-based sessions per week for another 10 weeks (collectively referred to as "post-CT AE RT"). During "post-CT AE RT," otherwise healthy participants performed a combination of aerobic intervals (4×[4 minutes at 75%-85% + 4 minutes at 40%-65% VO 2 /HR reserve]) and continuous-intensity exercise. Participants were encouraged to attend supervised sessions as often as possible, but no strict expectations were established around adherence.
Outcome Measures
Serial HR rest and Resting Blood Pressure Measurements During CT AE RT The timing of outcome measures relative to enrollment and the intervention is shown in Figure 1 . During CT AE RT, HR rest and blood pressure were measured approximately once per week before supervised sessions at approximately the same time of day. HR rest was measured on an FT1 HR monitor (Polar, Lachine, Quebec) as the lowest HR (excluding ectopic beats) during the last 30 seconds of a 5-minute period of quiet, seated rest, with back against the chair and feet flat on the floor, arms and legs uncrossed [10] . Test-retest reliability (1-5 days apart) for this assessment is an error of 1.6 AE 0.6 (mean AE standard deviation) beats per minute (bpm), and a coefficient of variation of 1.7 AE 0.6%. Blood pressure was measured at the end of the 5 minutes of rest as the average of two measurements 60 seconds apart with a validated automatic monitor (Omron HEM-907; Omron, Scarborough, Ontario) [11] .
Standardized Time Points of Physical Assessments
The timing of four physical assessments was standardized across participants to assess changes across the treatment trajectory. Timing of the "baseline" study assessment varied from prechemotherapy to within the first half of chemotherapy treatments depending on patient recruitment and enrollment. The "end CT AE RT" assessment was within 1 week after completion of radiation, or for those not receiving radiation, was one chemotherapy cycle length (1-3 weeks) after the last treatment. The "10w post-CT AE RT" assessment took place approximately 10 weeks after CT AE RT completion. The final, or "5-6m post-CT AE RT," assessment corresponded with completion of the intervention, 5-6 months after completion of CT AE RT. Assessments were typically performed at the same time of day for each participant. Prior to each assessment, participants were asked to not eat, drink caffeine or alcohol, smoke cigarettes, or consume nonvital drugs for at least 3 hours, and in the previous 24 hours, to not exercise strenuously, but to aim to hydrate and sleep well.
During the physical assessment, HR rest and resting blood pressure were measured similar to methods described above. Aerobic fitness was assessed as estimated peak volume of oxygen consumption (VO 2 ) by a modified Balke protocol [12] treadmill test with 3-minute stages, that was terminated at 70% of age-predicted [13] HR reserve (using current HR rest ), followed by a cooldown at 2.0 mph and 0%. Participants were asked to abstain from talking or holding handrails during the test. HRs at the end of each stage, and at 2 minutes into the cooldown, were recorded. The VO 2 corresponding to the treadmill speed and grade for each stage of the test was estimated using a metabolic equation for treadmill walking [14] . We have previously demonstrated accuracy of this equation for exercise prescription during and after chemotherapy for breast cancer [15] . The peak VO 2 was estimated by extrapolating the linear relationship between the HR at the end of each stage and the corresponding estimated VO 2 to age-predicted peak HR. The error introduced by using age-predicted HR is minimized by the use of change scores for these data. The HR recovery was calculated as the difference between the peak HR during the test and the HR at 2 minutes into the cooldown. The HR response to the onset of exercise (HR onset ) was calculated as the difference in HR between the end of the first stage and HR rest .
Prevalence of Abnormal HR rest and Resting Blood Pressures
The prevalence of tachycardia (HR rest >100 bpm), bradycardia (HR rest <50 bpm), and systolic or diastolic hypertension (blood pressure >140 or >90 mmHg) or hypotension (blood pressure <100 or <60 mmHg) [16] was assessed for each physical assessment, and using all weekly measures during CT AE RT.
Physical Activity Performed
Supervised exercise attendance was calculated as sessions attended divided by total possible sessions. A modified version of the Minnesota Leisure Time Physical Activity Questionnaire [17] was administered at the "baseline" and "5-6m post-CT AE RT" assessments in reference to the Figure 1 . Timing of standardized time points for assessment of resting heart rate, blood pressure, heart rate recovery after exercise, and weekly serial assessments of resting heart rate and blood pressure relative to study enrollment and the exercise intervention. Abbreviations: CT AE RT, chemotherapy with or without radiation; m, months; w, weeks. previous 6 months. The "5-6m post-CT+RT" questionnaire included both supervised and home-based exercise. Moderate-to-vigorous physical activity (MVPA; all aerobic activity with metabolic equivalent ≥3.0) and metabolic equivalent (MET)-hours per week for all reported activities were calculated.
Descriptive and Confounding Variables
Demographics and menopausal status were collected at baseline by questionnaire. Treatment characteristics, complete blood counts, medical history, and medications were extracted from medical records. The length of time enrolled in the study (and exercising) concurrent to CT AE RT ("Study + CT AE RT length") was calculated as weeks between the "baseline" and "end CT AE RT" assessments, whereas the total length of chemotherapy treatment was time between the first and last treatment.
Statistical Analysis
The time course of HR rest and resting systolic (SBP rest ) and diastolic blood pressure (DBP rest ) was assessed independent of other factors first using mixed linear models with participant as a random effect. The number of days since the last chemotherapy treatment was used to characterize the trajectory within the first 14 days of all chemotherapy cycles. The number of days since the first chemotherapy treatment was used to characterize the trajectory across the course of chemotherapy. Parabolic relationships were investigated when the residuals distribution appeared non-normal.
Second, the association of exercise, treatment, and other potential explanatory factors with the variation in change in HR rest , SBP rest , and DBP rest throughout chemotherapy treatment was assessed via computation of all possible combinations of mixed linear models and assignment of an Akaike information criterion score and weight. Independent variable importance was calculated by summing the weights of all models where the independent variable was included that summed to 95% of total weight. Next, HR rest and blood pressure were compared across the treatment trajectory using the average of all available measures that occurred prior to chemotherapy ("prechemotherapy"), during chemotherapy, and during radiation, as well as the values measured at the "end CT AE RT," "10w post-CT AE RT," and "5-6m post-CT AE RT" assessments using linear mixed models and Tukey post hoc tests. A Cochran's Q test with McNemar's test for post hoc comparisons were used to compare prevalence of tachycardia, hypertension, and hypotension across these time points.
Lastly, treatment and exercise-related predictors of ΔHR rest and ΔHR recovery during CT AE RT ("end CT AE RT" minus "baseline" assessments) and post-CT AE RT ("5-6m post-CT AE RT" minus "end CT AE RT" assessments) were identified using univariate general linear models. The treatment-related categorical independent variables tested included receiving anthracyclines, trastuzumab, radiation (either side), left-sided radiation, radiation to either internal mammary chain, hormonal therapy, and hormonal therapy type (none/tamoxifen/aromatase inhibitor). Independent physical activity/fitness-related continuous variables tested included supervised exercise attendance during CT AE RT and during chemotherapy alone, Δaerobic fitness, and MVPA and MET-hours. Exercise attendance during CT AE RT was also categorized into tertiles, but then dichotomized to 0%-66%, and ≥67% due to low cell size for <33%. Other potentially explanatory independent variables tested included "baseline" and change values of body weight, BMI, waist circumference, blood pressures (systolic, diastolic, mean), aerobic fitness, HR recovery , HR onset , and HR rest , as well as age, self-reported baseline menopausal status, history of heart disease (of any type) or hypertension, number of comorbid conditions, currently receiving hypertensive medications, "study + CT AE RT length," and total length of chemotherapy treatment. Hormonal therapy and "5-6m post-CT AE RT" MVPA and MET-hours were used only for post-CT AE RT. For post-CT AE RT, the "end CT AE RT" test value was used as the baseline value, and change in variables during CT AE RT as well as concurrent changes during the post-CT AE RT were tested as independent variables.
Significant or borderline significant (p ≤ .100) variables were then entered into a backward multiple regression with a p value for entry of .050 and p value for removal of .100. The Levene's test was used to ensure equality of error variances for the model. A collinearity tolerance statistic >0.2 was ensured for all variables in the final model. SPSS version 24.0 (IBM Corporation, Armonk, NY) and R version 3.3.1 were used for all analyses and figures.
Results
Participants
One hundred nine patients were referred during study recruitment (August 2013 to October 2014); 16 were ineligible and 20 declined participation. Seventy-three patients (78% of those eligible) enrolled. Nine participants (12%) withdrew; all available data were included. The primary results of the trial, including significant improvements in weekly minutes of MVPA and resistance training, are reported elsewhere [9] . As the "baseline" assessment was completed prior to starting chemotherapy ("prechemotherapy") in only 51% (n = 37) of participants as per eligibility for the primary trial, analyses were also completed including only these participants, but did not generally change overall trends; any discrepancies from results including all participants are noted. A post hoc power analysis was conducted conservatively using the n = 37 with "prechemotherapy" measures. Using R version 3.3.1, a p value of .05, and an F-test with repeated measures design provided >80% power to detect the effect sizes in HR rest (power = 0.99), SBP rest (power = 0.8), and DBP rest (power = 0.84) that were observed in this study between "prechemotherapy" and chemotherapy. Table 1 describes participant characteristics, whereas Figure 2A and 2B depict the changes in hemoglobin and hematocrit across chemotherapy. Ninety-five percent of participants were anemic (<120 g/L hemoglobin) for at least one treatment cycle. with number of days since the last treatment (p < .001).
The peak HR rest occurred at 7.6 days after receipt of a treatment (Fig. 3A) . Across the first four cycles (minimum number received), there appeared to be sequentially higher HR rest peaks (Fig. 3B ). Across the course of chemotherapy, a significant parabolic relationship was also demonstrated (p < .001), with the peak occurring at 76 days after the start (Fig. 3C ). Days since last chemotherapy and since chemotherapy start were highly important variables when including other factors in the model explaining ΔHR rest during chemotherapy. Other highly important variables associated with ΔHR rest during chemotherapy included hematocrit, SBP rest , and DBP rest , as well as tertiles of exercise attendance during chemotherapy. Receiving anthracyclines and trastuzumab were moderately important variables ( Table 2 ). When those without a "prechemotherapy" baseline were excluded, days since last chemotherapy, SBP rest , and DBP rest were no longer important variables.
Across the adjuvant treatment trajectory, average HR rest was highest during chemotherapy compared with all other time points (all p < .001), and remained elevated above prechemotherapy during radiation (p < .001) and at "end CT AE RT" (p = .004; Fig. 3D ). By "10w post-CT AE RT," HR rest was not different than prechemotherapy (p = .941). Resting tachycardia was present at least once in 32% of participants during chemotherapy, which was significantly higher than all other time points (all 0%-1%, p < .001). Resting bradycardia did not occur.
SBP rest and DBP rest Changes During Chemotherapy and Across the Adjuvant Treatment Trajectory
In terms of the time course of changes in blood pressure during chemotherapy, there was a significant parabolic relationship (p < .001) between SBP rest and number of days since the last treatment, with the nadir occurring at day 7.5 (Fig. 4A ). There was no significant within-cycle effect on DBP rest . SBP rest and DBP rest exhibited significant negative linear relationships with the number of days since chemotherapy start (p = .018, p = .039, respectively; Fig. 4B ). When other factors were included in the model explaining ΔSBP rest during chemotherapy, days since last chemotherapy treatment was moderately important and days since chemotherapy start was no longer an important variable. Highly important variables associated with ΔSBP rest during chemotherapy included receiving anthracyclines, the most recently measured hematocrit, and tertiles of exercise attendance during chemotherapy, whereas receiving trastuzumab was moderately important ( Table 2) . For DBP rest , time was not an important variable when other factors were included. Instead, hematocrit and tertiles of exercise attendance during chemotherapy were highly important, and treatment with anthracyclines and trastuzumab were moderately important variables explaining ΔDBP rest during chemotherapy ( Table 2) .
Across the adjuvant treatment trajectory, SBP rest did not significantly change from "prechemotherapy" to during chemotherapy (p = .307), but was significantly elevated at "10w post-CT AE RT" and "5-6m post-CT AE RT" relative to chemotherapy (both p < .001), and relative to radiation at "5-6m post-CT AE RT" (p = .008; Fig. 4C ). DBP rest was significantly reduced during chemotherapy relative to "prechemotherapy" (p = .002) and remained reduced during radiation (p = .015). By "10w post-CT AE RT," DBP rest was not different than prechemotherapy (p = .922; Fig. 4D ). The prevalence of systolic (3%-14%, p = .130) or diastolic (0%-10%, p = .183) hypertension was not different between time points. The prevalence of systolic hypotension was significantly higher during chemotherapy (51%) than radiation (19%, p = .003) and all other time points (3%-10%, all p < .001); prevalence during radiation was higher than the remaining time points (all p < .040). The prevalence of at least one instance of diastolic hypotension was also significantly higher during chemotherapy (29%) than radiation (12%, p = .008) and all other time points (3%-4%, all p < .001); prevalence during radiation was also higher than the remaining time points (all p < .040).
Factors Associated with Changes in HR rest and HR recovery During CT AE RT and Post-CT AE RT
The independent predictors and multiple regression models of ΔHR rest and ΔHR recovery during CT AE RT and post-CT AE RT are listed in Table 3 . The treatment-related factors that were predictive of impaired HR recovery and elevated HR rest were receiving anthracyclines, trastuzumab, and left-sided radiation. The physical activity/fitness-related factors that were predictive of increased HR recovery and less HR rest elevation were baseline and Δaerobic fitness, as well as supervised exercise attendance.
DISCUSSION
The main findings in this study of early-stage breast cancer patients receiving adjuvant chemotherapy and participating in an exercise program are the following: (a) HR rest increased within and successively across chemotherapy treatments; (b) within a chemotherapy cycle, the peak HR rest and the SBP rest nadir occurred at the 8th day after receipt of treatment; (c) SBP rest and DBP rest decreased linearly across the course of chemotherapy; (d) receiving cardiotoxic systemic therapies, hematocrit and hemoglobin levels, and supervised exercise attendance were associated with the changes in HR rest and blood pressure that occurred during chemotherapy; (e) during chemotherapy, tachycardia and hypotension occurred in one third and half of patients, respectively; and (f ) receipt of cardiotoxic treatments was associated with elevated HR rest and impaired HR recovery during CT AE RT, although objective indicators of exercise training during CT AE RT predicted improvements in these measures.
Tachycardia and diastolic hypotension occurred in almost one third and systolic hypotension in half of participants during chemotherapy treatment but were resolved by "end CT AE RT." Therefore, the primary implications of these conditions would be for practitioners providing oncology care or exercise guidance during chemotherapy. Oncologists and nurses performing physical examinations or subjective assessments of patient well-being should be aware of the pattern of incremental increases in HR rest and decreases in blood pressure that result in high prevalence of tachycardia and hypotension. Both conditions could result in patient symptoms (e.g., dizziness or lightheadedness, difficulty in changing body position, feelings of high heart rate) and a potential need for hypertension medication dose adjustments. Exercise professionals working with patients receiving chemotherapy should be aware of the prevalence of tachycardia and hypotension, regularly monitor for them, and adjust exercise plans as necessary. For exercise prescription and monitoring in the current study, we followed the 2010 American College of Sports Medicine exercise guidelines for cancer patients [14] of using HR rest >100 bpm, SBP rest >145 mmHg, and DBP rest >95 mmHg as contraindications to exercise training or testing. SBP rest <85 mmHg is also recommended as a contraindication, and there is no minimum for DBP rest . We did observe (but did not quantify) instances of dizziness and lightheadedness throughout chemotherapy, but often participants felt quite well in the face of hypotension and were able to exercise safely when counseled to change body positions slowly (e.g., sit to stand, or bending over to pick up weights) and ensure performance of ≥5-minute gradual warm-up and cool-down. Given the relatively common occurrence of hypotension, additional exercise guidelines may be required. We recommend monitoring HR rest and blood pressure after completion of an exercise session to ensure a normal return to pre-exercise measures, especially in the case of hypotension. Practitioners could also provide general recommendations for management of autonomic or orthostatic intolerance disorders to this patient population. In addition to exercise, these include ensuring adequate hydration, increasing salt intake, and avoiding bed rest [18] . Further, if resting is required during days of ill health, seated in bed would be the preferred position over lying supine to prevent severe deconditioning [18] . The autonomic nervous system regulates the regional and systemic circulation via changes in HR, arterial blood pressure, and peripheral vascular tone [5] . HR rest is influenced by numerous factors, but the major determining factor of HR rest is a combination of sympathetic stimulation and parasympathetic withdrawal [7] . Consistent with our findings, cross-sectional studies have reported elevated HR rest (+15-17 bpm) in breast cancer patients during and years after treatment relative to untreated breast cancer patients or healthy controls [3, 19, 20] . Elevated HR rest is of clinical interest as it is independently associated with increased risk of cardiovascular disease and mortality [21, 22] . In the current study, we demonstrated that HR rest increased with time since the last chemotherapy treatment, with some recovery prior to receiving the subsequent treatment, but that each subsequent treatment has a cumulative effect, such that there is a significant sustained average increase (+11 AE 1 bpm) over the course of chemotherapy. There is evidence that other chemotherapy treatment side effects including fatigue may follow a similar cyclical pattern in which the peak occurs several days after each treatment, followed by partial recovery, such that there is a cumulative increase over consecutive treatment cycles [23]. This pattern of treatment symptoms matches our clinical research observations. On this basis, we hypothesize that a relationship exists between the patterns in physiological variables and patient-reported (i.e., subjective) treatment symptoms. In terms of implications for the exercise professionals working with cancer patients during chemotherapy, we suggest that exercise volume and target HRs for intensity prescription should be prescribed to accommodate for the cyclical fluctuations in chemotherapy symptoms and HR rest , respectively. If possible, we suggest that HR rest be measured prior to every exercise session or at least once per week.
Little is known regarding the mechanisms for elevated HR rest with chemotherapy treatment. Reduced hemoglobin is a logical mechanism mediating the increase in HR rest, given its role in oxygen delivery. However, hematocrit, but not hemoglobin, was an important explanatory variable for ΔHR rest during chemotherapy, suggesting a role for plasma volume. SBP rest and DBP rest were also highly important explanatory variables, and changes during chemotherapy were in opposite directions for HR rest and blood pressure, which may suggest a role for baroreflex mediation. Additionally, a worsening in HR recovery and HR onset were predictive of >40% of the variance in ΔHR rest . Parasympathetic reactivation may be the predominant mechanism with 2+ minute HR recovery measures [7] , as within the current study. HR onset likely predominantly represents a reduction in vagal discharge [24] . Therefore, this finding indicates that changes in the regulation of vagal tone may also be an important mechanism for ΔHR rest .
Known cardiotoxic treatments were also predictors of ΔHR rest as well as ΔHR recovery . Receiving radiation to the left breast was predictive of a 7-beat increase in HR rest during CT AE RT, and a 4-beat reduction in HR recovery post-CT AE RT. A similar effect was previously reported with mediastinal radiation treatment, in which high-frequency HR variability (parasympathetic activity marker) was reduced, whereas the ratio of low-to-high-frequency (sympathovagal balance) was elevated [25] .
Receiving anthracyclines and trastuzumab were moderately important explanatory variables for ΔHR rest and Δblood pressure during chemotherapy, and were significant predictors of a 5-8-beat worsening of ΔHR rest and ΔHR recovery during CT AE RT. Importantly, supervised exercise attendance . Solid line and shaded area denotes mean and 95% confidence intervals. a Significantly different from chemotherapy. b Significantly different from radiation. Abbreviations: BP rest , resting blood pressure; CT AE RT, chemotherapy with or without radiation; DBP rest , resting diastolic blood pressure; SBP rest , resting systolic blood pressure. Autonomic Function and Breast Cancer Treatment ≥67% (i.e., at least twice per week) during CT AE RT was associated with a 6-beat improvement in both variables, potentially counteracting the negative effect of these cardiotoxic therapies. Furthermore, supervised exercise attendance (as a continuous variable) was a predictor of improvement in HR recovery , but not HR rest during chemotherapy alone or CT AE RT, suggesting a dose-response relationship for ΔHR recovery but a minimum threshold for effects on ΔHR rest . Despite the strong established link between aerobic fitness and autonomic function in other populations, longitudinal studies assessing this relationship in cancer populations are lacking [6] . In the current study, a reduction in aerobic fitness during CT AE RT was the strongest independent predictor of an elevated HR rest and was also an independent predictor of impaired HR recovery both during and post-CT AE RT. However, given that our measure of aerobic fitness was estimated without gas analysis, these findings should be interpreted with caution and need to be confirmed using cardiopulmonary exercise testing.
A history of heart disease predicted a 12-beat worsening of HR recovery during CT AE RT, but neither a history of hypertension nor use of hypertension medications were predictive of any changes. Age and postmenopausal status are known to increase the risk of cardiovascular disease in women [26] , and potentially in the breast cancer population [27] , and were also not predictors. Lakoski et al. have hypothesized that the weight gain and visceral adiposity common in breast cancer patients could be a source of autonomic dysfunction [6] . We did not find relationships between baseline levels or changes in body weight, BMI, or waist circumference with HR rest or HR recovery .
This study is the first to provide prospective data on changes in clinical indices that reflect cardiovascular autonomic function across and between adjuvant treatments for breast cancer. Our study sample is generalizable to the breast cancer population by including a wide range of ages, multiple ethnicities, comorbid conditions, and common treatments. However, this heterogeneity may also limit 90% CI reported for these borderline significant variables (0.10 ≤ p > .05). Abbreviations: -, not significant for this model; bpm, beats per minute; CI, confidence interval; CT AE RT, chemotherapy with or without radiation; DBP rest , resting diastolic blood pressure; HR onset , cardiac response to the onset of exercise; HR recovery , heart rate recovery after exercise; HR rest , resting heart rate; MAP rest , resting mean arterial pressure; mL/kg/minute, millilitres of oxygen per kilogram of body weight per minute; SBP rest , resting systolic blood pressure.
internal validity of our results. Although there is no nonexercise control group, the range of exercise attendance allowed for assessment of associations between exercise volume and our outcome measures. However, our data are likely biased by having fewer weekly measurements for those attending the exercise sessions less frequently. Our results regarding the influence of aerobic fitness are limited by our indirect measure. Lastly, our 5-6-month follow-up to completion of CT AE RT may not have been long enough to capture delayed cardiotoxic effects. Overall, these limitations should be considered in the interpretation of these results.
CONCLUSION
This was a longitudinal study of the association of cardiotoxic cancer therapies and exercise training with clinical indices of cardiovascular autonomic control. Among women with breast cancer enrolled in in an exercise program offered as supportive care, receiving anthracyclines, trastuzumab, and left-sided radiation treatments were associated with elevations in HR rest , reductions in blood pressure, and impairments of HR recovery . During chemotherapy, resting tachycardia and hypotension were common, occurring in one third and half of women. However, exercise training, particularly attendance of at least two out of three weekly, supervised sessions, and an improvement in aerobic fitness appear to mitigate the treatment-related changes. These preliminary findings using clinical measures of cardiovascular autonomic function warrant future research into the role of exercise training during and after cardiotoxic cancer therapies using more rigorous assessment methods.
